Disclaimer

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Transforming the treatment of aortic regurgitation

JenaValve is redefining what it means to treat patients with severe aortic regurgitation.

The Trilogy System

The only TAVR solution for severe
aortic regurgitation (AR)*

The Trilogy Valve

Data presented from the ALIGN-AR Trial

Learn More
Experts at conference

Innovations in TAVR:
The JenaValve Trilogy System

Learn More
Drs. Sam Dawkins and Matti Adam at EuroPCR 2024
About Us

JenaValve is a global medical device company
dedicated to supporting physicians

We are developing innovative medical device technology that conclusively
addresses the needs of patients with structural heart disease.
Learn More
The Trilogy System

Latest News

View All
Press
JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet
March 28, 2024
JenaValve Announces Publication of ALIGN-AR Pivotal Trial Results in The Lancet
Read More
Press
JenaValve’s Trilogy THV System Highlighted at CRT 2024
March 19, 2024
JenaValve’s Trilogy THV System Highlighted at CRT 2024
Read More
Press
JenaValve Announces Partnership with the ASE to Advance Detection and Diagnosis of AR
November 16, 2023
JenaValve Announces Partnership with the ASE to Advance Detection and Diagnosis of AR
Read More

Upcoming Events

View All

Get in touch today to learn more about JenaValve and the Trilogy System








    *Required

    *Indications: The JenaValve Trilogy Heart Valve System is indicated for use in patients with native symptomatic, severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement (AVR), with an STS score ≥ 8% at 30 days, or other comorbidities (e.g., porcelain aorta, frailty, chest wall irradiation) that are not captured by the STS risk calculator.

    Contraindications: The JenaValve Trilogy Heart Valve System is contraindicated for use in patients who have known hypersensitivity or contraindication to Nitinol (titanium and/or nickel), an anti-coagulation/anti-platelet regimen or contrast medium that cannot be managed with premedication, or who have active bacterial endocarditis or other active infections.

    US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.